Individuals ≥40 years of age at the time of first signed informed consent at Visit 1a
Participants must have at least 1 first-degree relative (biological parent, sibling, or child) with confirmed pulmonary fibrosis (idiopathic pulmonary fibrosis \[IPF\], idiopathic nonspecific interstitial pneumonia \[NSIP\], and/or pulmonary fibrosis due to known genetic cause \[e.g. short telomere syndrome, mucin 5B (MUC5B) mutation, surfactant protein mutations\])
High resolution computed tomography (HRCT) scan with evidence of interstitial lung abnormalities involving at least 5% of a single lung zone or interstitial lung disease (ILD), based on central evaluation
Forced vital capacity (FVC) ≥80% of predicted normal at Visit 1b
You may not be if
Prior known pulmonary fibrosis that, in the opinion of the Investigator, requires treatment with approved therapies
Prebronchodilator forced expiratory volume in 1 second (FEV1)/FVC \<0.7 at Visit 1b
HRCT findings consistent with probable or definite usual interstitial pneumonia (UIP) pattern
Any medical condition that is known to predispose to the development of pulmonary fibrosis (e.g. known connective tissue disease)
Clareo Health | A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
